^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan for Non-Small Cell Lung Cancer Therapy
Published date:
05/15/2015
Excerpt:
Immunomedics, Inc...announced that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a Fast Track development program sacituzumab govitecan, the Company's lead antibody-drug conjugate (ADC), for the treatment of patients with metastatic non-small cell lung cancer (NSCLC)...
